Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,419 Mln
Revenue (TTM)
$674 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.4
Industry P/E
28.02
EV/EBITDA
28.6
Div. Yield
0 %
Debt to Equity
1.5
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
21,651,100
CFO
$325.24 Mln
EBITDA
$483.84 Mln
Net Profit
$-25.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ANI Pharmaceuticals (ANIP)
| 19.4 | 15.3 | 2.8 | 12.8 | 36.8 | 16.7 | 0.7 |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
ANI Pharmaceuticals (ANIP)
| 0.3 | 37.1 | -12.7 | 58.7 | -52.9 | 37.0 | -30.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ANI Pharmaceuticals (ANIP)
|
66.0 | 1,419.5 | 674.1 | -21.1 | 0.0 | -5 | -- | 3.4 |
| 17.9 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 7.9 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 101.7 | 5,065.9 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 95.2 | |
| 54.1 | 10,547.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.9 | |
| 42.2 | 7,923.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 74.3 | 7,569.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.1 | 11.1 | |
| 13.4 | 6,684.9 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.9 | 1.0 | |
| 84.4 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.3 | |
| 8.9 | 10,410.5 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel,... as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. Read more
President, CEO & Director
Mr. Nikhil Lalwani
President, CEO & Director
Mr. Nikhil Lalwani
Headquarters
Baudette, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ANI Pharmaceuticals Inc (ANIP) stood at $ 1,494 Mln as on 31-Mar-25
The share price of ANI Pharmaceuticals Inc (ANIP) is $66.03 (NASDAQ) as of 23-Jun-2025 16:00 EDT. ANI Pharmaceuticals Inc (ANIP) has given a return of 36.82% in the last 3 years.
ANI Pharmaceuticals Inc (ANIP) has a market capitalisation of $ 1,419 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ANI Pharmaceuticals Inc (ANIP) is 3.39 times as on 20-Jun-2025, a 28% discount to its peers’ median range of 4.74 times.
Since, TTM earnings of ANI Pharmaceuticals Inc (ANIP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ANI Pharmaceuticals Inc (ANIP) and enter the required number of quantities and click on buy to purchase the shares of ANI Pharmaceuticals Inc (ANIP).
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
The CEO & director of Mr. Nikhil Lalwani. is ANI Pharmaceuticals Inc (ANIP), and CFO & Sr. VP is Mr. Nikhil Lalwani.
There is no promoter pledging in ANI Pharmaceuticals Inc (ANIP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| ANI Pharmaceuticals Inc. (ANIP) | Ratios |
|---|---|
|
Return on equity(%)
|
-4.96
|
|
Operating margin(%)
|
0.03
|
|
Net Margin(%)
|
-3.12
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ANI Pharmaceuticals Inc (ANIP) was $0 Mln.
$0.47
(
